President Donald Trump is pushing forward with his Most Favored Nation (MFN) plan to reduce prescription drug costs, but the policy is facing significant pushback from his traditional allies.
Policy details and opposition The MFN plan aims to link the drug prices paid by the U.S. government to the lowest prices paid by other economically advanced nations. Trump claims this could cut prices by up to 90%. However, a coalition of over 50 free-market and conservative organizations has urged Congress to reject the proposal. They argue that MFN imports “socialist price controls,” which could limit access to new cures and undermine U.S. global competitiveness against rivals like China.
Implementation tools and confidential deals Rather than seeking new laws through Congress, the Trump administration is utilizing executive tools:
-
Confidential Agreements: So far, 16 pharmaceutical giants (including Pfizer and Eli Lilly) have reached private deals with the HHS to avoid the mandated MFN pricing regime.
-
TrumpRx.gov: A government direct-to-consumer online program for patients paying with cash.
-
Tariff Relief: Offered to drugmakers that cut prices or commit to investing in U.S.-based R&D and manufacturing facilities.
Expert perspective and transparency concerns John Barkett, a former senior policy advisor in the Biden administration, notes that Trump is leveraging every federal tool available because lower drug prices remain a rare point of bipartisan consensus among voters. However, Barkett highlighted a critical lack of transparency, as the specifics of the deals remain hidden. The advocacy group Public Citizen has filed a FOIA lawsuit to force the disclosure of documents related to these negotiations.